SFX by Ex Libris Inc.

Title:	Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases
Source:	Acs Medicinal Chemistry Letters [1948-5875] Hille, Ulrike yr:2011

Basic

Full text

Full text available via American Chemical Society Journals

Year:

Volume:

Issue:

Start Page:

Full text available via PubMed Central

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Fleseriu, M. "Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome." The Journal of clinical endocrinology and metabolism 97.6 (2012): 2039-2049.
description	2.	Oster, A. "Novel estrone mimetics with high 17Î²-HSD1 inhibitory activity." Bioorganic & medicinal chemistry 18.10 (2010): 3494-3505.
description	3.	Masterson, D. "A divergent approach to the preparation of cysteine and serine analogs." Journal of peptide science 14.11 (2008): 1151-1162.
description	4.	Castinetti, F. "Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone." Neuroendocrinology 92.1 (2010): 125-130.
description	5.	Juszczak, A. "Cushing's disease: current trends in treatment.(Disease/Disorder overview)." Clinical Practice 10.6 (2013): 713-.
description	6.	Rizk, A. "Treatment Options in Cushing's Disease." Clinical Medicine Insights 6.2012 (2012): 75-84.
description	7.	Colao, A. "A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease." The New England journal of medicine 366.10 (2012): 914-924.
description	8.	Bacsa, I. "Synthesis of A-ring halogenated 13α-estrone derivatives as potential 17β-HSD1 inhibitors." Steroids 104 (2015): 230-236.
description	9.	Agren, D. "Cysteine Synthase (CysM) of Mycobacterium tuberculosis Is an O-Phosphoserine Sulfhydrylase EVIDENCE FOR AN ALTERNATIVE CYSTEINE BIOSYNTHESIS PATHWAY IN MYCOBACTERIA." The Journal of biological chemistry 283.46 (2008): 31567-31574.
description	10.	Baldwin, I. "Kinase array design, back to front: biaryl amides." Bioorganic & medicinal chemistry letters 18.19 (2008): 5285-9.
description	11.	O'Donnell, J. "Cesium (Z)-2-Carbomethoxyethenethiolate: A Reagent for the Preparation of (Z)-2-Carbomethoxyethenyl Thioethers Including Selected Cysteine and Homocysteine Derivatives." European journal of organic chemistry 4 (2009): 547-553.
description	12.	Gallos, J. "A new strategy for the stereoselective synthesis of unnatural alpha-amino acids." Tetrahedron 61.3 (2005): 565-574.
description	13.	Young, William F F. "Role for adrenal venous sampling in primary aldosteronism." Surgery 136.6 (2005): 1227-35.
description	14.	MIURA, M. "Design, synthesis and biological activity of selective and orally available TF/FVIIa complex inhibitors containing non-amidine P1 ligands." Bioorganic & medicinal chemistry 15.1 (2007): 160-173.
description	15.	Fonvielle, M. "New competitive inhibitors of cytosolic (NADH-dependent) rabbit muscle glycerophosphate dehydrogenase." Bioorganic & medicinal chemistry letters 17.2 (2007): 410-413.
description	16.	Trainer, P. "New options for the medical treatment of Cushing's syndrome." Indian journal of endocrinology and metabolism 17.2 (2013): 245-248.
description	17.	Morgan, Farah H. "Mifepristone for Management of Cushing's Syndrome." Pharmacotherapy 33.3 (2013): 319-329.
description	18.	Fleseriu, Beverly M K M. "A New Therapeutic Approach in the Medical Treatment of Cushing's Syndrome: Glucocorticoid Receptor Blockade with Mifepristone." Endocrine practice 19.2 (2013): 1-36.
description	19.	Pedroncelli, Alberto M. "Medical treatment of Cushing's disease: somatostatin analogues and pasireotide." Neuroendocrinology 92 Suppl 1.supp.S1 (2010): 120-124.
description	20.	RA, F. "Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease." New England Journal of Medicine, The 362.19 (2010): 1846-1848.